ApoPharma's oral iron chelator Ferriprox is approved by FDA

10/16/2011 | MedPage Today (free registration)

The FDA approved ApoPharma's Ferriprox, or deferiprone, for iron overload in patients with thalassemia who failed to respond adequately to other chelation therapies. The agency required a post-marketing test of Ferriprox's clinical benefit. ApoPharma also must evaluate the drug in transfusion-dependent patients with sickle cell disease.

View Full Article in:

MedPage Today (free registration)

Published in Briefs: